1. Board of directors approved he Audited standalone financial results of the company for the quarter and year ended 31.03.2025 together with Audit report. 2. Board of Directors have recommended ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.2 pts more than Nifty Microcap 250 and 5.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved audited standalone financial results for Q4 and full year ended 31 March 2025. Full-year revenue from operations rose modestly to Rs. 31,906.32 lakhs (vs Rs. 30,043.84 lakhs in FY24, ~6% growth), while full-year profit after tax surged to Rs. 2,355.91 lakhs (vs Rs. 859.48 lakhs in FY24, ~174% growth). Q4 FY25 saw revenue decline ~25% YoY to Rs. 7,540.87 lakhs, though the company swung to a Q4 profit of Rs. 552.18 lakhs from a loss of Rs. 692.19 lakhs in Q4 FY24. The Board recommended a final dividend of Rs. 8 per share (80% on face value of Rs. 10). The auditor (Saghesh Kumar & Associates) issued an unqualified opinion. Managing Director Dr. S N Sasidharan Kartha resigned on health grounds effective 20 May 2025, and his son Mr. Saran S Kartha (previously Joint Managing Director) was appointed as the new Managing Director for a 3-year term effective 21 May 2025.
Strong full-year earnings and a generous 80% dividend are positive for shareholders, though the sharp Q4 revenue decline and very thin operating cash flow (Rs. 97.39 lakhs vs Rs. 611.83 lakhs) signal working-capital pressure. The leadership transition is smooth (family succession) and unlikely to disrupt operations, but the health-driven exit of the long-time MD may warrant monitoring.